Metal-based epigenetic therapeutics in cancer: Mechanisms, targets, and opportunities for overcoming drug resistance.

Astapczyk J, Szewczyk-Roszczenko OK, Vassetzky Y, Czarnomysy R

Open source

DOI
10.1016/j.phrs.2026.108449
Published
2026 Oct
Container
Pharmacological research
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.phrs.2026.108449,
  title = {Metal-based epigenetic therapeutics in cancer: Mechanisms, targets, and opportunities for overcoming drug resistance.},
  author = {Astapczyk J and Szewczyk-Roszczenko OK and Vassetzky Y and Czarnomysy R},
  year = {2026},
  journal = {Pharmacological research},
  doi = {10.1016/j.phrs.2026.108449},
  url = {https://doi.org/10.1016/j.phrs.2026.108449}
}

RIS

TY  - JOUR
TI  - Metal-based epigenetic therapeutics in cancer: Mechanisms, targets, and opportunities for overcoming drug resistance.
AU  - Astapczyk J
AU  - Szewczyk-Roszczenko OK
AU  - Vassetzky Y
AU  - Czarnomysy R
PY  - 2026
JO  - Pharmacological research
DO  - 10.1016/j.phrs.2026.108449
UR  - https://doi.org/10.1016/j.phrs.2026.108449
ER  - 

APA

J, A., OK, S., Y, V., & R, C. (2026). Metal-based epigenetic therapeutics in cancer: Mechanisms, targets, and opportunities for overcoming drug resistance.. Pharmacological research. https://doi.org/10.1016/j.phrs.2026.108449

Source records